Kim et al [22] showed that CRC patients with elevated COX-2 expression experienced favourable recurrence-free survival compared to COX-2-low tumours with overexpressing cancers having the late onset of recurrence [22]. This evidence concerns the gene PTGS2 and colorectal carcinoma.